{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T09:16:56Z","timestamp":1705310216181},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/maj.0b013e318251406c","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T23:45:46Z","timestamp":1335397546000},"page":"360-363","source":"Crossref","is-referenced-by-count":3,"title":["The \u201cKnowns\u201d and \u201cUnknowns\u201d of Biologic Therapy in Ankylosing Spondylitis"],"prefix":"10.1016","volume":"343","author":[{"given":"Lianne","family":"Gensler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Inman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Clegg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e318251406c_bb0005","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0010","first-page":"905","article-title":"Assessment of SpondyloArthritis International Society","volume":"70","author":"van der Heijde","year":"2011","journal-title":"2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0020","first-page":"442","article-title":"Assessment in AS\u201d international working group; European League Against Rheumatism","volume":"65","author":"Zochling","year":"2006","journal-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0025","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0030","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized","volume":"52","author":"van der Heijde","year":"2005","journal-title":"placebo-controlled trial (ASSERT). Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0035","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebocontrolled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0040","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","article-title":"Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis","volume":"67","author":"Davis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0050","first-page":"1270","article-title":"Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group","volume":"59","author":"Braun","year":"2008","journal-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0055","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomized double-blind, placebo-controlled study (SPINE)","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0065","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2007.082529","article-title":"Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis","volume":"67","author":"van der Heijde","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0070","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/rheumatology\/kep022","article-title":"Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion","volume":"48","author":"Rudwaleit","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0075","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1445-5994.2007.01599.x","article-title":"Infliximab in severe active ankylosing spondylitis with spinal ankylosis","volume":"38","author":"Cheung","year":"2008","journal-title":"Intern Med J"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0080","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0085","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumor necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0090","first-page":"1751","article-title":"Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept","volume":"32","author":"Davis","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0095","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","article-title":"Predictors of response to anti-TNF therapy in AS: results from the British Society for Rheumatology Biologics Register","volume":"49","author":"Lord","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0105","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumor necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0110","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0115","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","article-title":"Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years\u2014early clinical response predicts long-term outcomes","volume":"59","author":"Baraliakos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl 3","key":"10.1097\/MAJ.0b013e318251406c_bb0120","first-page":"344","article-title":"An immediate decrease in serum VEGF levels helps in predicting a major response in patients with AS who were started on infliximab: results from the ASSERT biomarker study","volume":"70","author":"Baraliakos","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0125","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of TNF-alpha blocking therapy in AS: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NORDMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0135","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3054","article-title":"Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy","volume":"12","author":"Rudwaleit","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0140","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/art.22236","article-title":"Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four week study","volume":"55","author":"Cantini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0145","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10354-010-0795-0","article-title":"Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis","volume":"169","author":"Haberhauer","year":"2010","journal-title":"Wien Med Wochenschr"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0150","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.24838","article-title":"Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis","volume":"61","author":"de Vries","year":"2009","journal-title":"Arthritis Care Res"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0155","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10067-010-1528-x","article-title":"Circulating levels of interleukin-6 vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFa inhibitors","volume":"29","author":"Pederseon","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0160","first-page":"2030","article-title":"M03\u2013606 Study Group. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis","volume":"35","author":"Maksymowych","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0165","first-page":"1911","article-title":"Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis","volume":"32","author":"Maksymowych","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0170","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/art.24865","article-title":"Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab","volume":"61","author":"Braun","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard.2007.084426","article-title":"Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis","volume":"68","author":"Visvanathan","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0180","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/art.22887","article-title":"Health related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized, controlled study","volume":"57","author":"Davis","year":"2007","journal-title":"Arthritis Care Res"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0185","first-page":"1346","article-title":"Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis","volume":"35","author":"Revecki","year":"2008","journal-title":"J Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0190","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/acr.20233","article-title":"Golimumab reduces sleep disturbances in patients with active ankylosing spondylitis: results from a randomized placebo-controlled trial","volume":"62","author":"Deodhar","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/rheumatology\/ker169","article-title":"Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study","volume":"51","author":"Kristensen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0200","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2003.017327","article-title":"Impact of anti-tumor necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis","volume":"63","author":"Listing","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0205","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","article-title":"Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0210","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/ard.2009.109702","article-title":"Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0215","first-page":"661","article-title":"The formation of autoantibodies and antibodies to TNF-a blocking agents in relation to clinical response in patients with ankylosing spondylitis","volume":"28","author":"Arends","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0220","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidences of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0225","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the antitumor necrosis factor agents infliximab and eanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0230","first-page":"1270","article-title":"Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group","volume":"15","author":"Braun","year":"2008","journal-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0235","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0240","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e318251406c_bb0245","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker-na\u00efve patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"suppl 3","key":"10.1097\/MAJ.0b013e318251406c_bb0250","first-page":"130","article-title":"Patients with active ankylosing spondylitis show clinical response to a second cycle of rituximab\u2014follow up of an open label clinical trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"suppl 3","key":"10.1097\/MAJ.0b013e318251406c_bb0255","first-page":"343","article-title":"Tocilizumab for treatment of refractory spondylo-arthritis: report of 5 patients","volume":"70","author":"Del Castillo","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"suppl 3","key":"10.1097\/MAJ.0b013e318251406c_bb0260","first-page":"127","article-title":"The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis","volume":"70","author":"Baeten","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T21:25:56Z","timestamp":1543008356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915309642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0002962915309642"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e318251406c","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}